ZESTORETIC 12.5 MG
HYDROCHLOROTHIAZIDE : 12.5 MG LISINOPRIL : 10 MG · DIN 02103729 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is ZESTORETIC?
ZESTORETIC 12.5 MG contains HYDROCHLOROTHIAZIDE : 12.5 MG LISINOPRIL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02103729, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZESTORETIC used for?
Treatment of essential hypertension in patients for whom combination therapy is appropriate. Not indicated for initial therapy or renovascular hypertension.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02103729 |
|---|---|
| Brand name | ZESTORETIC |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 12.5 MG LISINOPRIL : 10 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 12.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09BA03 LISINOPRIL AND DIURETICS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Feb-2022 |
How is it administered?
Individualize dosage. Not for initial therapy. Titrate components. Once daily dosing. If CrCl 10-30 mL/min, start lisinopril at 2.5-5.0 mg/day. Swallow whole; do not crush/split.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to full monograph section 11).
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to lisinopril, HCTZ, or sulfonamides; history of ACEI-related angioedema; pregnancy; nursing; anuria; combination with sacubitril/valsartan or aliskiren (in specific patients).
Warnings and precautions
Fetal toxicity risk; hypotension; angioedema (can be fatal); non-melanoma skin cancer risk (HCTZ); neutropenia/agranulocytosis; dual blockade of RAS; aortic stenosis/hypertrophic cardiomyopathy.
What can be used instead?
Other Canadian products sharing ATC code C09BA03 LISINOPRIL AND DIURETICS. 12 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LISINOPRIL/HCTZ (TYPE Z) | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02362945 |
| LISINOPRIL/HCTZ (TYPE Z) | 12.5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02362953 |
| LISINOPRIL/HCTZ (TYPE Z) | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02362961 |
| SANDOZ LISINOPRIL HCT | 10 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02302365 |
| SANDOZ LISINOPRIL HCT | 20 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02302381 |
| SANDOZ LISINOPRIL HCT | 20 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02302373 |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02301768 |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02301776 |
| TEVA-LISINOPRIL/HCTZ (TYPE Z) | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02301784 |
| ZESTORETIC | 20 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02045729 |
Who else supplies LISINOPRIL AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LISINOPRIL AND DIURETICS appears in 493 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.